依那普利聯合氫氯噻嗪治療原發性高血壓30例臨床觀察
藥物與臨床
作者：陶泓利
[摘要] 目的 研究依那普利聯合氫氯噻嗪治療原發性高血壓的療效。 方法 采用回顧性方法分析我院自2013年1月～2014年1月收治的60例原發性高血壓患者的臨床資料，分為對照組及觀察組各30例，兩組患者治療前2周停服其他降壓藥物，對照組予依那普利，觀察組聯合應用氫氯噻嗪，連用8周。觀察比較兩組的療效及治療前後SBP及DBP水平變化情況。 結果 觀察組臨床總有效率（93.3%）明顯高於對照組（70.0%），兩組療效應用χ2檢驗處理，差異有統計學意義（P
[關鍵詞] 原發性高血壓；依那普利；氫氯噻嗪
[中圖分類號] R544.1 [文獻標識碼] B [文章編號] 1673-9701（2015）08-0084-03
[Abstract] Objective To investigate the effect of enalapril and hydrochlorothiazide in treatment of essential hypertension. Methods The clinical data of 60 patients with essential hypertension were analyzed in our hospital from January 2013 to January 2014， and they were divided into observation group and control group， 30 cases in each group， two groups of patients stopped taking other antihypertensive drugs two weeks before treatment， the control group was treated with enalapril， while the observation group was treated with enalapril and hydrochlorothiazide for eight weeks. Changes of SBP and DBP levels before and after treatment and efficacy were compared between the two groups. Results Total effective rate of observation group was 93.3%， the total effective rate of the control group was 70.0%， which was significant higher than the control group（P
[Key words] Hypertension； Enalapril； Hydrochlorothiazide
原發性高血壓治療的關鍵是有效地控製血壓，減少心、腦、腎等重要髒器的損害，有效降低並發症的發生率及病死率[1]。對原發性高血壓藥物治療不僅應考慮降壓效果，還須考慮患者長期用藥的耐受程度，以最大限度地減少抗高血壓藥物對患者心、腎等髒器的損害。血管緊張素轉換酶抑製劑與利尿劑均為1999年WHO/ISH高血壓治療指南推薦的首選藥[2]。依那普利屬於血管緊張素轉換酶抑製劑，氫氯噻嗪為利尿劑，本研究旨在探討依那普利聯合氫氯噻嗪治療原發性高血壓的療效，現報道如下。